行情

RGLS

RGLS

Regulus
NASDAQ

实时行情|Nasdaq Last Sale

1.040
-0.130
-11.11%
交易中 15:23 01/27 EST
开盘
1.160
昨收
1.170
最高
1.160
最低
1.000
成交量
27.19万
成交额
--
52周最高
1.740
52周最低
0.5000
市值
2,176.41万
市盈率(TTM)
-0.5632
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RGLS 新闻

  • 摩根大通:全球股市动荡之际正是买入良机
  • 新浪美股.53分钟前
  • 戈恩警告在日外国高管:你在拿自己的生命开玩笑
  • 新浪美股.58分钟前
  • 利比亚:几天之内石油生产可能接近完全停止
  • 新浪财经.1小时前
  • 欧洲央行官员警告称宽松政策加大市场下跌风险
  • 新浪财经.1小时前

更多

所属板块

生物技术和医学研究
-0.96%
制药与医学研究
-0.35%

热门股票

名称
价格
涨跌幅

RGLS 简况

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
展开

Webull提供Regulus Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。